Wednesday, December 10th, 2025: Day Two - ET (Eastern Time, GMT-05:00)
Despite billions invested in digital health, many solutions can stall during the pilot phase. This panel explores how strategic partnerships between pharma and health systems can unlock scalable, sustainable impact. Drawing from real-world case studies and experience collaborating with health systems and IDNs to deploy these solutions, we’ll discuss:
Creating win–win models that align incentives and ensure financial sustainability
Success drivers for pharma-led health IT solution deployment into clinical workflows
Partnering with medical associations and EMR integrators to accelerate scale
Embracing agile, test-and-learn approaches to refine and expand successful pilots
- Christopher Lisanti - Managing Director, Commercial Advisory Group – Consulting, Head, Customer and Digital Engagement, Syneos Health Consulting
- Jake Schutz - Managing Director, Digital Health Solutions, Syneos Health
- Tony Lanzone - Global Head of Consulting, Syneos Health
Step through the roadmap of capabilities required to leverage advanced analytical approaches
Discuss how basic table stakes data capabilities have expanded to include more innovative concepts that can provide deeper insights into product performance, and how a data strategy approach can help you get there
- Jeremy Daan - Senior Principal, Blue Fin Group
Explore innovative approaches to unifying multiple digital touchpoints, leveraging digital advancements to enable Patients to be the “CEO” of their healthcare journey
Learn from pioneering case studies where digital applications have accelerated patient care, streamlined medication management and enabled more personalized communications while lowering the cost of patient acquisition
- Dean Erhardt - President & CEO, D2 Solutions
Master the complexities of payer relationships, reimbursement methodologies and formulary decision-making processes that drive market access success
Develop expertise in financial structures, budget impact modeling and risk-sharing arrangements to create mutually beneficial partnerships
Identify high-value partnership models that address health system challenges while improving patient outcomes and optimizing pharmaceutical value propositions
- John Robicsek - AVP Strategy, Business and Program Development Pharmacy Administration Specialty Pharmacy Service, Advocate Health
